Clinical medicine

MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO

Tuesday, July 7, 2020 - 1:00pm

Preclinical data have demonstrated that THIO kills cancer cells by targeting and uncapping telomeres thereby inducing DNA damage.

Key Points: 
  • Preclinical data have demonstrated that THIO kills cancer cells by targeting and uncapping telomeres thereby inducing DNA damage.
  • The latest preclinical data showed this is complemented by an immunogenic effect, which may allow for more durable outcomes when used sequentially with immunotherapy.
  • In these preclinical studies published in Cancer Cell, investigators demonstrated that THIO leads to tumor regression through induction of innate and adaptive host immune system responses.
  • We believe the publication of these unprecedented immunogenic effects of THIO in Cancer Cell provides additional validation for this innovative program.

Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer

Tuesday, July 7, 2020 - 12:30pm

Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer.
  • We look forward to seeing results from the HEPANOVA trial and further exploring the potential of Tumor Treating Fields as a treatment for advanced liver cancer.
  • The safety and effectiveness of treatment with Tumor Treating Fields for liver cancer has not been established.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer.

Glytec and ThunderCat Technology Partner to Improve Glycemic Management at VA Hospitals

Tuesday, July 7, 2020 - 1:30pm

Glytec , the only provider of insulin management software across the continuum of care, and ThunderCat Technology , a Service-Disabled Veteran-Owned Small Business (SDVOSB) that delivers technology products and services to government organizations, today announced a partnership to help improve glycemic management within hospitals operated by the United States Department of Veterans Affairs (VA).

Key Points: 
  • Glytec , the only provider of insulin management software across the continuum of care, and ThunderCat Technology , a Service-Disabled Veteran-Owned Small Business (SDVOSB) that delivers technology products and services to government organizations, today announced a partnership to help improve glycemic management within hospitals operated by the United States Department of Veterans Affairs (VA).
  • Together, Glytec and ThunderCat will extend Glytecs reach into the VA health system by making Glytecs Glucommander software widely available to improve patient outcomes and reduce cost of care for the large population of veterans with diabetes.
  • However, that need is higher in VA hospitals because 25% of veteran patients are living with diabetes , compared to about 10% of the general public.
  • While inpatient glycemic management remains a broader issue across the U.S. health system, helping to improve care and outcomes at the VA is especially important and can have a very dramatic impact.

 Acessa Health Announces Positive Payer Coverage, with Over Half of Insured Americans Covered for the Procedure

Tuesday, July 7, 2020 - 1:00pm

(1) More than 156 million Americans are covered for the Acessa procedure, with expanded coverage over the last 12 months in Maryland, Massachusetts, North Carolina, North Dakota, Ohio, Pennsylvania, and Washington DC.

Key Points: 
  • (1) More than 156 million Americans are covered for the Acessa procedure, with expanded coverage over the last 12 months in Maryland, Massachusetts, North Carolina, North Dakota, Ohio, Pennsylvania, and Washington DC.
  • The Acessa procedure is designed to treat women with uterine fibroids and is clinically proven with long-term data as a safe alternative to hysterectomy and myomectomy.
  • (2)
    Acessa Health is a womens health innovator dedicated to advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids.
  • Although many patients may benefit from the Acessa Procedure, this treatment is not for everyone and results may vary.

Wound Closure & Advanced Wound Care Market Size Worth $1.69 Billion by 2027: Grand View Research, Inc.

Tuesday, July 7, 2020 - 9:35am

SAN FRANCISCO, July 7, 2020 /PRNewswire/ -- The global wound closure and advanced wound care market size is expected to reach USD 1.69 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.5% over the forecast period.

Key Points: 
  • SAN FRANCISCO, July 7, 2020 /PRNewswire/ -- The global wound closure and advanced wound care market size is expected to reach USD 1.69 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.5% over the forecast period.
  • Increasing incidence of chronic diseases globally, rising demand for wound dressing products and advanced wound care management, and growing number of sports injuries and road accidents are the key factors driving the market.
  • Rapidly increasing number of road accidents is leading to a rise in the demand for injury closure and advanced care products.
  • Grand View Research has segmented the global wound closure and advanced wound care market on the basis of product, application, end use, and region:
    Wound Closure & Advanced Wound Care Product Outlook (Revenue, USD Million, 2016 - 2027)

Wound Closure & Advanced Wound Care Market Size Worth $1.69 Billion by 2027: Grand View Research, Inc.

Tuesday, July 7, 2020 - 9:35am

SAN FRANCISCO, July 7, 2020 /PRNewswire/ -- The global wound closure and advanced wound care market size is expected to reach USD 1.69 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.5% over the forecast period.

Key Points: 
  • SAN FRANCISCO, July 7, 2020 /PRNewswire/ -- The global wound closure and advanced wound care market size is expected to reach USD 1.69 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.5% over the forecast period.
  • Increasing incidence of chronic diseases globally, rising demand for wound dressing products and advanced wound care management, and growing number of sports injuries and road accidents are the key factors driving the market.
  • Rapidly increasing number of road accidents is leading to a rise in the demand for injury closure and advanced care products.
  • Grand View Research has segmented the global wound closure and advanced wound care market on the basis of product, application, end use, and region:
    Wound Closure & Advanced Wound Care Product Outlook (Revenue, USD Million, 2016 - 2027)

U.S. Dermatology Partners is pleased to welcome Board Certified Dermatologist Amanda Champlain, MD to their Carrollton office July 7th

Tuesday, July 7, 2020 - 8:00am

CARROLLTON, Texas, July 7, 2020 /PRNewswire-PRWeb/ --U.S. Dermatology Partners is excited to welcome Board-Certified Dermatologist and Fellowship-Trained Laser and Cosmetic Dermatologic Surgeon Dr. Amanda Champlain to its Carrollton office .

Key Points: 
  • CARROLLTON, Texas, July 7, 2020 /PRNewswire-PRWeb/ --U.S. Dermatology Partners is excited to welcome Board-Certified Dermatologist and Fellowship-Trained Laser and Cosmetic Dermatologic Surgeon Dr. Amanda Champlain to its Carrollton office .
  • Dr. Champlain specializes in the use of lasers and energy-based devices, facial rejuvenation, and body contouring.
  • She has authored several peer-reviewed journal articles and textbook chapters and has presented her work at national dermatology and aesthetic meetings.
  • The practice proudly serves Carrollton and the surrounding neighborhoods including Plano, Lewisville, Frisco, The Colony, Allen, Addison, and Dallas.

HOYA and Hitachi Announce Long Term Technical Collaboration and Supply Agreement Related to Endoscopic Ultrasound Systems

Monday, July 6, 2020 - 9:39am

TOKYO, July 6, 2020 - (JCN Newswire) - HOYA Corporation (TSE:7741) and Hitachi, Ltd. (TSE:6501) announced a five-year contract regarding Endoscopic Ultrasound Systems [EUS] by which, i) the parties will strengthen technical collaboration, and ii) Hitachi will continue supplying diagnostic ultrasound systems and ultrasound sensor-related parts used in EUS.

Key Points: 
  • TOKYO, July 6, 2020 - (JCN Newswire) - HOYA Corporation (TSE:7741) and Hitachi, Ltd. (TSE:6501) announced a five-year contract regarding Endoscopic Ultrasound Systems [EUS] by which, i) the parties will strengthen technical collaboration, and ii) Hitachi will continue supplying diagnostic ultrasound systems and ultrasound sensor-related parts used in EUS.
  • EUS consists of a diagnostic ultrasound system and ultrasound flexible endoscopes, and is used for examinations to evaluate the cancer staging in the liver, pancreas, and bronchus.
  • The Hitachi ultrasound technology is globally recognized as an important standard in EUS with high-quality imaging, advanced software modalities, and ease of use.
  • Hitachi and PENTAX Medical have been working together for more than 30 years and developing innovative technologies in EUS.

Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus

Monday, July 6, 2020 - 9:04pm

Patients reported the severity of their tinnitus symptoms using the Tinnitus Functional Index (TFI), a clinically-validated instrument, and by the daily reporting of their tinnitus loudness and annoyance.

Key Points: 
  • Patients reported the severity of their tinnitus symptoms using the Tinnitus Functional Index (TFI), a clinically-validated instrument, and by the daily reporting of their tinnitus loudness and annoyance.
  • The trial achieved its objectives by demonstrating a positive clinical signal for OTO-313 based on a TFI responder analysis, with a favorable safety profile.
  • Given these results, Otonomy intends to advance OTO-313 into full Phase 2 development which may include evaluation of a higher dose and/or retreatment with OTO-313.
  • Top-line results for the Phase 1/2 trial were as follows:
    43% of OTO-313 patients were responders at both Day 29 and Day 57 compared to 13% of placebo patients.

Quidel Announces Preliminary Revenue for Second Quarter 2020

Monday, July 6, 2020 - 10:00pm

Our second quarter was even stronger than we had expected, driven by demand for our COVID-19 Molecular Diagnostics and Rapid Immunoassay products.

Key Points: 
  • Our second quarter was even stronger than we had expected, driven by demand for our COVID-19 Molecular Diagnostics and Rapid Immunoassay products.
  • Later in the quarter, we completed the development of Sofia SARS Antigen, gained EUA clearance, and manufactured almost 4 million Sofia SARS Antigen cassettes in the quarter.
  • These preliminary results are based on managements initial analysis of operations for the quarter ended June 30, 2020.
  • The company expects to issue full financial results for the second quarter in late July.